The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Functional recovery in parkinsonian monkeys treated with GDNF
Abstract
Parkinson's disease results from the progressive degeneration of dopamine neurons that innervate the striatum. In rodents, glial-cell-line-derived neurotrophic factor (GDNF) stimulates an increase in midbrain dopamine levels, protects dopamine neurons from some neurotoxins, and maintains injured dopamine neurons. Here we extend the rodent studies to an animal closer to the human in brain organization and function, by evaluating the effects of GDNF injected intracerebrally in rhesus monkeys that have had the symptomatology and pathophysiological features of Parkinson's disease induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The recipients of GDNF displayed significant improvements in three of the cardinal symptoms of parkinsonism: bradykinesia, rigidity and postural instability. GDNF administered every four weeks maintained functional recovery. On the lesioned side of GDNF-treated animals, dopamine levels in the midbrain and globus pallidus were twice as high, and nigral dopamine neurons were, on average, 20% larger, with an increased fibre density. The results indicate that GDNF may be of benefit in the treatment of Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, growth factor–mediated prevention of neuronal loss in transection models has predicted protection from disease-specific mechanisms in other models22–25.”
From Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (2009) · cites this paper as [24]
Citations
Cites
Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206
Self-citationProtection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079
Self-citationNew stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 850
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654
A consideration of neural counting methods
Coggeshall, R. E. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90339-a · Cited by 540
Hoffer, B. J., Hoffman, A. F., Bowenkamp, K., Huettl, P. F., Hudson, J., Martin, D., Lin, L.-F. H., & Gerhardt, G. A. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90218-6 · Cited by 453
Self-citationGDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo
Kearns, C. M., & Gash, D. M. (1995) · Brain Research · doi:10.1016/0006-8993(94)01366-p · Cited by 379
Self-citationBankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308
Flagged first, then by citations
Research works printed but not linked: 2
- Jellinger, K. Adv. Neurol. 45, 1–18 (1986).
- Hornykiewicz, O. & Kish, S. J. Adv. Neurol. 45, 19–34 (1986).
Cited by
Sorted by citations
Items 901–946 of 946
敬也, 小. (1998) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.87.1149
Earl, C. D., Sautter, J., Oertel, W. H., & Kupsch, A. R. (1998) · Springer eBooks · doi:10.1007/978-3-642-58731-3_44
Nitta, A., Murai, R., Maruyama, K., & Furukawa, S. (2002)
Surgical Treatment of Parkinson Disease and Other Movement Disorders
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50010-3
Investigational surgical therapies
Issar, N. M., & Neimat, J. S. (2013) · CRC Press eBooks · doi:10.1201/b14361-28
Gene Therapy Applications for Parkinson’s Disease
Torres, E. M., Monville, C., & Dunnett, S. B. (2006) · CRC Press eBooks · doi:10.3109/9781420016390-10
Emerging and Experimental Neurosurgical Treatments for Parkinson's Disease
Stone, S. S. D., Mukhida, K., & Lozano, A. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5316-3.00086-1
Infusion Therapy for Movement Disorders
Hsieh, J. C. Y., & Penn, R. D. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374248-3.00045-8
Cytokines and Neurodegeneration
Parvathy, S., & Murphy, G. M. (2005) · CRC Press eBooks · doi:10.1201/9781420039849.ch9
Cell-Based Therapies for Parkinson’s Disease: Preclinical and Clinical Perspectives
Sebastiano, A. R. D., Staudt, M. D., Benoit, S. M., Xu, H., Hebb, M. O., & Schmid, S. (2016) · InTech eBooks · doi:10.5772/63747
Rodent Ischemia Models of Embolism and Ligation of the Middle Cerebral Artery
Borlongan, C. V., Nishino, H., Wang, Y., & Sanberg, P. R. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-691-1_20
Connor, B. J., & Bohn, M. (1999) · Gene therapy & molecular biology
Schurig, K. (2011) · Qucosa (Saxon State and University Library Dresden)
Experimental Models and New, Emerging Therapies for Parkinson Disease
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50012-7
Validations of apomorphine-induced BOLD activation correlations in hemiparkinsonian rhesus macaques
Quintero, J. E., Ai, Y., Andersen, A. H., Hardy, P., Grondin, R., Guduru, Z., Gash, D. M., Gerhardt, G. A., & Zhang, Z. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101724
Self-citationDesign and Development of Small Molecules from Somatic, Stem Cell Reprogramming, and Therapy
Guttula, P. K., & Gupta, M. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-18375-2_10
1-metil-4-fenil-1,2,3,6-tetrahidropiridinin (MPTP) Parkinson hastalığı üzerindeki etkileri
Akbulut, H. (2019) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2019.010
Medical treatment of Parkinson disease
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00006-8
Gene Therapy for Parkinson's Disease
Andersen, K. (2012) · CommonKnowledge Research Repository (Pacific University Oregon)
Glial-cell-line-derived neurotrophic factor: gene promoter and receptors
(1999) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.9.6.779
Investigational surgical therapies
Issar, N. M., & Neimat, J. S. (2013) · Informa Healthcare eBooks · doi:10.3109/9781841849096.025
Barker, R. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735165397.793557354
Chen, J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.012
Airavaara, M., Voutilainen, M. H., Wang, Y., & Hoffer, B. J. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.08.021
Self-citationNeuroinflammatory mechanisms of Parkinson's Disease
Mangano, E. N. (2011) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2011-09648
Parkinsons Disease: Recent Advancement and Future Aspects
Indrakshi, T., Aparna, A., Krishna, H., Aashul, N., & Rajawat, J. S. (2022) · International Journal for Research in Applied Science and Engineering Technology · doi:10.22214/ijraset.2022.47171
Fountoulakis, K. N. (2022) · Springer eBooks · doi:10.1007/978-3-031-10351-3_9
Neuroprotection in Parkinson's Disease
Pascual, A., Villadiego, J., Hidalgo‐Figueroa, M., Méndez‐Ferrer, S., Gómez-Díaz, R., Toledo‐Aral, J. J., & López‐Barneo, J. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781849731843-00162
Grondin, R., Littrell, O. M., Ai, Y., Huettl, P. F., Pomerleau, F., Quintero, J. E., Gash, D. M., Zhang, Z., & Gerhardt, G. A. (2024) · Medical Research Archives · doi:10.18103/mra.v12i2.5074
Self-citationPossible Roles of Epigenetics in Stem Cell Therapy for Parkinson’s Disease
Krubaa, P. (2024) · SBV Journal of Basic Clinical and Applied Health Science · doi:10.4103/sbvj.sbvj_13_24
Shamadykova, D., & Pavlova, G. V. (2024) · Журнал высшей нервной деятельности им И П Павлова · doi:10.31857/s0044467724060049
GDNF Gene Therapy for Parkinson’s Disease
Kells, A. P., Laar, A. D. V., & Bankiewicz, K. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_5
Growth factors and regulated cell death in neurodegenerative disorders
Numakawa, T., & Kajihara, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-32852-7.00010-3
Oertel, W. H., Pogarell, O. M., Kupsch, A. R., & Hartmann, A. (1997) · Springer eBooks · doi:10.1007/978-3-662-03509-2_9
Zhang, Y.-J., Huang, Y., Lu, Z., & Yuan, Z. (2026) · ACS Materials Au · doi:10.1021/acsmaterialsau.6c00024
Thérapie cellulaire de la maladie de Parkinson : transplantation intranigrale vs intrastriatale
Droguerre, M. (2015) · theses.fr (ABES) · doi:10.70675/228fb270z39e3z41efzaafaz7ebcb6733014
Neumane, S. (2011) · theses.fr (ABES) · doi:10.70675/4cb9b747z6b13z46eazb3cbzb58a8bffabf2
Powell, W. H., Annett, L. E., Depoortère, R., Newman‐Tancredi, A., & Iravani, M. M. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00251
Terpstra, K. J. (2014) · MacSphere (McMaster University) · doi:10.71548/12972
Neurotrophic Factor Therapy: GDNF and CNTF
Chen, E.-Y., Fox, D., & Kordower, J. H. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00015-2
Get fitter (much) faster. Your workouts don't have to last long--but they have to be hard.
Sifferlin, A. (2015) · PubMed
Prospects for Gene Therapy for Central Nervous System Disease
Tuszynski, M. H. (2005) · Elsevier eBooks · doi:10.1016/b978-012738903-5/50016-3
Metadata
- Authors
- Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., Hoffer, B. J., & Gerhard, G. A.
- Affiliations
- University of Kentucky (US)
- Venue
- Nature
- Published
- 1996-03
- Volume
- 380
- Issue
- 6571
- Pages
- 252-255
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971258758
- Cited by
- 955
- References
- 22
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 10 · 2023: 9 · 2022: 20 · 2021: 16 · 2020: 23 · 2019: 18 · 2018: 20 · 2017: 13 · 2016: 21 · 2015: 27 · 2014: 24 · 2013: 30 · 2012: 27
- FWCI
- 51.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, glial cell line-derived neurotrophic factor, MPTP-induced parkinsonism, rhesus monkeys, dopaminergic neurons, midbrain dopamine, globus pallidus, nigral neurons, bradykinesia, rigidity, postural instability, functional recovery, neuroprotection, neurotrophic therapy
- MeSH terms
- Animals, Dopamine, Female, Humans, Macaca mulatta, Mesencephalon, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Parkinson Disease, Recombinant Proteins, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Glial Cell Line-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
